Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
Go back to Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1110.08 +8.00 (0.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1102.08 | 52 Week High | $88.16 | |||
| Open | $1117.00 | 52 Week Low | $67.88 | |||
| Day High | $1122.02 | P/E | 256.96 | |||
| Day Low | $1079.22 | EPS | $4.32 | |||
| Volume | 1,836,903 | |||||
